Summary
In 2022, an increase in invasive Group A Streptococcal infections (iGAS) was observed in the Netherlands. A particular increase was seen among children, therefore we aimed to assess risk factors for iGAS in children aged 6 months to 5 years. A prospective case-control study was conducted between February and May 2023. We approached parents of notified iGAS cases to complete a questionnaire on exposures during 4 weeks prior to disease onset. Controls were recruited via social media and matched to cases (10:1) on sex and birthyear. Conditional logistic regression was performed to estimate odds ratios (OR) of exposures. For the analysis we included 18 cases and 103 controls. Varicella prior to onset of iGAS disease was reported in 2 (11%) cases and 1 (1%) control (OR: 12.0, 95% CI: 1.1-139.0). Exposure to GAS-like illnesses impetigo, pharyngitis and scarlet fever was reported in 8 (44%) cases and 15 (15%) controls (OR: 7.1, 95% CI: 1.8-29.0). Our findings are in line with previous studies by identifying varicella as a risk factor for iGAS among young children and highlight the association with non-invasive GAS infections in the community as a possible source of transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Dutch Ministry of Health, Welfare and Sports.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Centre for Clinical Expertise at the RIVM verified whether this work complied with either the specific conditions as stated in article one of the Dutch law for Medical Research Involving Human Subjects (WMO) or with the EU Clinical Trial Directive (2001/20/EC), and was of the opinion that the research did not fulfill these conditions. Therefore, no formal ethical approval was required. A Data Privacy Impact Assessment (DPIA) was conducted to adhere to the data protection legislation. A digital informed consent of parents of cases and controls was requested before the online questionnaire could be opened.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors, in aggregated form to ensure participant privacy.
